hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06306378 id: XJTU1AF2023LSK-481 briefTitle: The Relationship Between Social Memory Disorders and Sleep Spindles in Children With Autism Spectrum Disorder overallStatus: RECRUITING date: 2023-12-04 date: 2024-03-30 date: 2024-04-30 date: 2024-03-12 date: 2024-03-12 name: First Affiliated Hospital Xi'an Jiaotong University class: OTHER name: Xi'an TCM Hospital of Encephalopathy briefSummary: Research background and project basis
Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder characterized by social disorders and repetitive stereotypical behavior. Social memory impairment is a significant feature of ASD patients, and the specific pathogenesis of social memory impairment in ASD patients is currently unclear, and there are no objective indicators to measure social memory levels. Sleep spindle wave is a special brain wave in sleep that is closely related to memory consolidation. However, no one has yet studied the impact of sleep spindles on social memory.
Exploring the correlation between sleep spindles and social memory in the population, providing reference for the auxiliary diagnosis of social memory disorders in children with ASD. conditions: Autism Spectrum Disorder studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 60 type: ESTIMATED name: social memory levels and spindle levels measure: Recognition accuracy measure: Response delay time measure: Sleep spindle density measure: Sleep spindle average duration measure: Sleep spindle amplitude measure: Sleep spindle frequency sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: First Afflicated Hospital Xian Jiaotong University status: RECRUITING city: Xi'an state: Shaanxi zip: 710061 country: China name: Yan Li, MD., PhD. role: CONTACT phone: 13720418610 email: liyanxjtu@xjtu.edu.cn name: Dongqi Cui, PhD. role: CONTACT phone: 18501059233 email: 18501059233@163.com lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06306365 id: PI-DOC003-WBOA briefTitle: Effects of Modern Board Games on Well Being in Older Adults acronym: JUMEMO3e+ overallStatus: RECRUITING date: 2024-02-07 date: 2024-06-28 date: 2024-06-28 date: 2024-03-12 date: 2024-03-12 name: European University Miguel de Cervantes class: OTHER name: Centro Doctor Villacián, Valladolid, Spain briefSummary: The aim of the study is to assess the effects of an intervention using modern board game-based learning in a sample of older individuals. The evaluation will focus on determining if there is a change in executive functions, social participation, and participants' perception of well-being. conditions: Executive Functions studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A quasi-experimental methodology will be employed, involving both a control group and an experimental group. Randomized control trial. primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: No masking. count: 35 type: ESTIMATED name: Modern board game-based learning measure: Examination for Mental Disorders of the Elderly measure: Trail Making Test to evaluate Executive Functions measure: Assessment of quality of life in older adults and people with disabilities measure: Psychometric development and practical use sex: ALL minimumAge: 65 Years maximumAge: 120 Years stdAges: OLDER_ADULT facility: European University Miguel of Cervante status: RECRUITING city: Valladolid zip: 47012 country: Spain name: Azael J. Herrero, PhD role: CONTACT phone: +34983001000 email: jaherrero@uemc.es name: Raquel Martínez-Sinovas, PhD role: CONTACT phone: +34983001000 email: rmsinovas@uemc.es lat: 41.65518 lon: -4.72372 hasResults: False
nctId: NCT06306352 id: 1070 id: NL82999.091.22 type: OTHER domain: CCMO briefTitle: Vibrotactile Feedback in Exoskeletons overallStatus: COMPLETED date: 2023-03-06 date: 2023-06-21 date: 2023-06-21 date: 2024-03-12 date: 2024-03-12 name: Sint Maartenskliniek class: OTHER name: ABLE Human Motion S.L. name: Netherlands Organisation for Scientific Research briefSummary: This study aims to investigate the impact of providing discrete vibrotactile feedback related to weight shift and step initiation on exoskeleton use in individuals with motor-complete SCI. conditions: Spinal Cord Injuries studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 7 type: ACTUAL name: Vibrotactile feedback measure: Walking distance covered measure: Reach path ratio measure: Reach time measure: User experience questionnaire measure: Dutch version of the Quebec User Evaluation of Satisfaction with Assistive Technology (D-QUEST) - only including the eight items related to user satisfaction with the assistive device measure: Dutch System Usability Scale (D-SUS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sint Maartenskliniek city: Nijmegen country: Netherlands lat: 51.8425 lon: 5.85278 hasResults: False
nctId: NCT06306339 id: hzVSF_v13-0015 briefTitle: A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug) overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-05 date: 2025-07 date: 2024-03-12 date: 2024-03-12 name: ImmuneMed, Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the efficacy and safety of intravenous infusions of burfiralimab (hzVSF-v13) when added to Disease-Modifying Antirheumatic Drug (DMARD) treatment as Standard of Care (SOC) in participants with moderate to severe Rheumatoid Arthritis (RA). conditions: Moderate to Severe Rheumatoid Arthritis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Burfiralimab name: SOC (Standard of care) name: Placebo measure: Proportion of participants achieving clinical response according to the ACR 20 criteria at Week 12 measure: Clinical response at Week 12, assessed as the attainment of an LDA (Low Disease Activity) state defined measure: Clinical response at Week 12, assessed as remission defined measure: Improvement of physical function at Week 12 measure: Pain relief at Week 12 assessed by the (mean) change from Baseline measure: Health-related quality of life at Week 12, assessed as the change from Baseline sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Medical Center Urtrecht city: Utrecht state: GA country: Netherlands lat: 52.09083 lon: 5.12222 hasResults: False
nctId: NCT06306326 id: pkussfatgrafting briefTitle: 3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2028-12-01 date: 2029-03-01 date: 2024-03-12 date: 2024-04-18 name: Peking University class: OTHER briefSummary: Treatment of craniofacial deformities is a significant topic in oral and maxillofacial surgery, and autologous fat grafting has become one of the main methods for treating facial concave deformities. However, the instability of its treatment effect has always been a bottleneck in this field, mainly due to the uncertain absorption rate of transplanted fat. This project aims to use advanced the 3dMD face system (3dMD) (3dMD Inc, Atlanta, Ga) technology to precisely measure the facial volume changes before and after autologous fat grafting to address this issue. By performing autologous fat grafting surgery on 100 patients with craniofacial deformities that meet the research criteria, 3dMD technology will be used for facial three-dimensional scanning preoperatively, immediately postoperatively, and at six months postoperatively to obtain facial volume data. Then, through precise data analysis, we will calculate the fat absorption rate and study the effects of individual factors on treatment outcomes through correlation regression analysis. conditions: Adipocytes conditions: Autografts conditions: Imaging, Three-Dimensional / Methods studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: 3dMD technology measure: Fat Retention Rate measure: Patient Satisfaction sex: ALL minimumAge: 3 Years maximumAge: 80 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06306313 id: ReoGo briefTitle: Effects of Robot-Assisted Rehabilitation on Upper Extremity Functions in Chronic Stroke overallStatus: RECRUITING date: 2024-03-07 date: 2024-05-07 date: 2024-05-14 date: 2024-03-12 date: 2024-04-05 name: Pamukkale University class: OTHER briefSummary: The most common problem caused by stroke is motor activity limitation that reduces muscle movement and mobility. But stroke can also lead to sensory and cognitive impairment. Additionally, the ability to independently carry out activities of daily living and participate in social and community life is greatly reduced. Up to 85% of stroke patients experience hemiparesis immediately after stroke, while 55% to 75% of survivors continue to experience reduced quality of life with motor impairments.
It requires long-term physical rehabilitation to achieve functional recovery in the upper extremity, maximum independence and the highest possible quality of life. Different methods can be used to achieve these results, but there is no clear evidence yet as to which treatment method gives the best results. Scientific evidence shows that a multifactorial approach and high-intensity treatment accelerates the motor recovery of the upper extremities in stroke rehabilitation. Passive and active upper extremity movements appear to increase motor recovery due to their effects on somatosensory input, motor planning, soft tissue properties and spasticity.
In recent years, robotic devices have emerged that have been proven to improve the motor performance of the upper extremity in chronic stroke patients. There are also studies showing that robotic device-assisted upper extremity therapy can contribute to the development of sensorimotor skills in plegic patients. However, in the current literature, there is still a need for randomized controlled studies in this field. The aim of this study is to investigate the effects of robot-assisted therapy on upper extremity functions and daily living activities in the rehabilitation of chronic stroke patients. After the demographic data of the cases in both groups are obtained, evaluations will be made before the study. Then, the study group will receive conventional physiotherapy in a single session of 45 minutes a day, 3 days a week for 4 weeks, and in addition robot-assisted therapy with the ReoGo Upper Extremity Exoskeleton Robot in a single session of 60 minutes a day, 5 days a week for 4 weeks. The control group will receive only conventional physiotherapy in a single session of 45 minutes a day, 3 days a week for 4 weeks. The initial evaluations will be repeated after the end of the treatment period. conditions: Stroke conditions: Upper Extremity Paresis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 24 type: ESTIMATED name: ReoGo name: Conventional Physiotherapy measure: Fugl Meyer Upper Extremity Evaluation Scale measure: Functional Independence Scale sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pamukkale University status: RECRUITING city: Denizli country: Turkey name: Fatih Tekin, Prof. role: CONTACT phone: +90258 296 4264 email: fzt.ftekin@hotmail.com lat: 37.77417 lon: 29.0875 hasResults: False
nctId: NCT06306300 id: 445957/2020-4 briefTitle: Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil) acronym: HCVPCL05/20 overallStatus: RECRUITING date: 2022-07-04 date: 2025-12-31 date: 2025-12-31 date: 2024-03-12 date: 2024-03-25 name: Oswaldo Cruz Foundation class: OTHER name: Conselho Nacional de Desenvolvimento Científico e Tecnológico briefSummary: Up to 650,000 people in Brazil are living with chronic hepatitis c virus (HCV) infection. Hepatitis C is a silent disease, and up to 20% of cases can progress to liver cirrhosis and its complications. Rapid tests for diagnosis of HCV infection and non-invasive methods for detecting liver cirrhosis are available in the Brazilian Public Health System. Additionally, safe and highly effective drugs (direct-acting antivirals, DAAs) have been delivered for free for hepatitis C treatment by the Brazilian Unified Health System (Sistema Único de Saúde, SUS) since 2015. Sustained virological response (SVR) rates with DAAs in studies conducted in Brazil and Latin America were higher than 90%. Despite the availability of rapid tests for early diagnosis and effective drugs, the HCV continuum of care remains deficient in Brazil. It is estimated that only 10% of individuals known to have hepatitis C achieve HCV cure (SVR). This is explained by multiple barriers from diagnosis to treatment access, such as low rates of population screening (HCVST are not available in Brazil) and few available slots in tertiary centers for hepatitis C treatment by specialists. International studies have described that SVR rates by simplified hepatitis C treatment performed by non-specialists in the Primary Care System were similar to those treated in tertiary centers by specialists (standard-of-care). However, the optimal strategy for managing hepatitis C within the Brazilian-SUS remains unclear.This project aims to evaluate the improve of the HCV continuum of care by a implementation of a test-and-treat strategy in the Primary Care System in Brazil. The project consists of two parallel studies (and a sub-study).
The project consists of two parallel studies (and a sub-study). Study I is a population-based cross-sectional screening study using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit. The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (participants included in Study I). Study II is a phase IV open-label randomized clinical trial to evaluate the non-inferiority of simplified and decentralized hepatitis C treatment ("Simplified-and-Decentralized (SD) HCV treatment"; experimental arm) compared to specialist reference treatment ("Standard-of-Care (SC) HCV treatment"; control arm) within the SUS. conditions: Hepatitis C studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Study I is a population-based cross-sectional screening study (n=30,000 individuals) to determine the prevalence of HCV infection in people attending a Basic Health Care Unit. The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (n=1,500 participants included in Study I). Study II is a phase IV open-label randomized clinical trial (1:1) to evaluate the non-inferiority of simplified and decentralized hepatitis C treatment ("Simplified-and-Decentralized (SD) HCV treatment"; experimental arm) compared to specialist reference treatment ("Standard-of-Care (SC) HCV treatment"; control arm) within the SUS. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 30000 type: ESTIMATED name: Specialist - Epclusa 400Mg-100Mg Tablet name: Non- specialist - Epclusa 400Mg-100Mg Tablet measure: Prevalence of HCV infection measure: The effectiveness of the HCV treatment with test results. measure: Usability of the result of a self-test HCV measure: Proportion between positive and negative measure: Participants with fibrosis/cirrhosis measure: Participants who denied the treatment measure: cost per detected participant measure: Unscheduled visits during treatment measure: Improvement of liver fibrosis stage measure: Quality of life data measure: Cost of treatment for participant measure: Adherence to treatment measure: Participant´s Ability to use the test measure: Participant preference for types of tests measure: Participant understanding to interpret his result measure: Test Performance measure: Test Accuracy sex: ALL minimumAge: 18 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Evandro Chagas National Institute of Infectious Diseases status: RECRUITING city: Rio de Janeiro state: Rio De Janeiro/RJ zip: 21040-360 country: Brazil name: Hugo Perazzo, PhD role: CONTACT phone: +5521 3865-9587 email: hugo.perazzo@ini.fiocruz.br lat: -22.90278 lon: -43.2075 facility: Hugo Perazzo status: RECRUITING city: Rio De Janeiro country: Brazil name: Hugo Perazzo, PhD role: CONTACT phone: +552138659587 email: hugo.perazzo@ini.fiocruz.br lat: -22.90278 lon: -43.2075 hasResults: False
nctId: NCT06306287 id: DA053660 briefTitle: Adolescent Screening and Personalized Intervention Resource for Enhancement of Behavioral Health and Substance Use acronym: ASPIRE overallStatus: RECRUITING date: 2024-02-15 date: 2024-11-30 date: 2025-04-30 date: 2024-03-12 date: 2024-04-22 name: Oregon Research Institute class: OTHER briefSummary: Only a small fraction of youth who are beginning to experience behavioral health problems and use alcohol or illicit drugs receive needed treatment services due to the lack of accessible, effective early intervention resources. The goal of this clinical trial is to compare a personalized brief web-based early intervention, eHealth Personalized Approach for Change Efficacy (ePACE), in which youth are offered choices regarding intervention content and desired level of engagement, to a "fixed", non-tailored brief intervention, eHealth Fixed Approach for Change Efficacy (eFACE) for adolescents with mild/moderate substance use and common co-occurring problems. Both ePACE and eFACE include a multi-problem screener that guides youths through a set of key integrated behavior change and counseling modules providing a cohesive focus on these four problem domains: drug abuse, interpersonal relations, negative emotions and stress. The main questions the trial aims to answer are:
nctId: NCT06306274 id: TACLE trial briefTitle: Topical Tacrolimus for Breast Cancer-related Lymphedema overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-11-30 date: 2025-11-30 date: 2024-03-12 date: 2024-03-12 name: Odense University Hospital class: OTHER briefSummary: The goal of this clinical trial is to investigate the effect of tacrolimus ointment in women with stage I or II breast cancer-related lymphedema. The main question it aims to answer are:
* If maintenance treatment is effective. Participants will be treated with either active drug or placebo once daily for six months followed by a six month maintenance periode with treatment twice weekly. Assessments will be performed at baseline, three, six, nine and 12 months. conditions: Lymphedema studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 80 type: ESTIMATED name: Tacrolimus name: Placebo measure: Lymphedema volume sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Odense University Hospital city: Odense zip: 5000 country: Denmark name: Frederik Gulmark Hansen role: CONTACT phone: +4521734450 email: frederik.c.gulmark.hansen@rsyd.dk lat: 55.39594 lon: 10.38831 facility: Zealand University Hospital city: Roskilde zip: 4000 country: Denmark name: Michael Rose role: CONTACT lat: 55.64152 lon: 12.08035 facility: Lillebaelt Hospital city: Vejle zip: 4000 country: Denmark lat: 55.70927 lon: 9.5357 hasResults: False
nctId: NCT06306261 id: TIMAEUS briefTitle: Controlling the Mental Health for a Better Response to Treatment in Patients With Ulcerative Colitis acronym: TIMAEUS overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-08 date: 2025-03-15 date: 2024-03-12 date: 2024-03-12 name: IRCCS San Raffaele class: OTHER briefSummary: The project aims to implement the Internet Of Thing (IoT) platform of the San Raffaele Hospital (OSR) with data from stress conditions perceived by the patient through the synergistic collaboration between patients, gastroenterologists and psychologists. conditions: Ulcerative Colitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: questionnaire measure: to evaluate mental stress/health as an impacting factor on UC progression sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Irccs Ospedale San Raffaele city: Milano zip: 20132 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06306248 id: PNRR-MAD-2022-12375716 briefTitle: Immune Activation, Neural Plasticity and Depression overallStatus: RECRUITING date: 2023-03-03 date: 2025-03-03 date: 2025-05-09 date: 2024-03-12 date: 2024-03-12 name: IRCCS San Raffaele class: OTHER briefSummary: Major depressive disorder (MDD) is a chronic, recurring and potentially life-threatening illness that affects up to 10% of the population across the globe.Increasing evidence indicates a clear link between immune dysfunction and MDD.Moreover, an activation of inflammatory pathways is associated to a lack of clinical response to antidepressants. Thus, the regulation of inflammation represents a potential approach to modulate the link between the living environment and antidepressant outcome. Light therapy combined with sleep deprivation hastens recovery, with benefits that can be perceived by patients during the first week of treatment. Alteration of the sleep-wake cycle and of sleep structure are core symptoms of MDD.The aims of the present project are (i) to show that neural plasticity and the environmental context are moderating factors of the therapeutic outcome of immune modulation and (ii) to exploit their interplay to set up novel and effective therapeutic strategies for MDD.This is a observational prospective study with non-invasive add-on procedures (Magnetic Resonance without contrast). In this study, 60 patients with a depressive episode in course of MDD and treated with a chronobiological intervention including total sleep deprivation (TSD) + light therapy (LT), as performed in clinical practice, will be studied. All participants enrolled in the study will receive Treatment As Usual (TAU), i.e., pharmacotherapy, chronobiological intervention plus clinical management. Drug prescription will be performed during the clinical management sessions.The study will have a total duration of 24 months. Each subject will participate in the study for 6 months, will undergo Magnetic Resonance Imaging (MRI) and clinical evaluation at baseline, after one week of chronobiological treatment and at 6 months follow-up. conditions: Mood Disorders conditions: Major Depressive Disorder conditions: Sleep Deprivation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Total sleep deprivation measure: BENEFICIAL EFFECT OF total sleep deprivation in inflamed vs non inflamed patients. measure: Neurobiological markers of prediction and progression of antidepressant treatment sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale San Raffaele status: RECRUITING city: Milan state: Mi zip: 20132 country: Italy name: Sara SP Poletti, phd role: CONTACT phone: 390226433156 email: poletti.sara@hsr.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06306235 id: 20.84-reva20.06 briefTitle: Are Non-participants of Conventional Centre-based Cardiac Rehabilitation Willing to Participate in Cardiac Telerehabilitation? overallStatus: COMPLETED date: 2020-10-12 date: 2021-07-31 date: 2021-07-31 date: 2024-03-12 date: 2024-03-12 name: Jessa Hospital class: OTHER briefSummary: Patients who are eligible for cardiac rehabilitation but do not want to participate will be offered to participate in an interview (part A of the study) or a tablet questionnaire (part B of the study).